Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients
NCT04634435
Age 18 - 75
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This is a scientific study where doctors are testing a new treatment for people with a type of cancer called multiple myeloma. The treatment involves taking cells from the patient's blood, adding some special substances to them, and then putting them back into the patient's body. The study will look at whether this treatment is safe and if it can help people who have a small amount of cancer left after their first treatment.
This is a scientific study where doctors are testing a new treatment for people with a type of cancer called multiple myeloma. The treatment involves taking cells from the patient's blood, adding some special substances to them, and then putting them back into the patient's body. The study will look at whether this treatment is safe and if it can help people who have a small amount of cancer left after their first treatment.
Third Opinion AI Generated Synopsis
Trial Summary
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission.
This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2 in the peri-transplant setting in MM patients with minimal residual disease (MRD+) in first or second remission.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
